
|Articles|September 22, 2016
Does Surveillance With CA-125 in Ovarian Cancer Benefit Patients?
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Subcutaneous Daratumumab Combination in NDMM
2
Developers Resubmit NDA for Rivoceranib/Camrelizumab in Unresectable HCC
3
Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma
4
FDA Grants BTD to Bezuclastinib Combo in Gastrointestinal Stromal Tumors
5



































